Since we found that the anti-tumor effects of 25 and 50 mg/kg OXi4503 are somewhat similar, and superior to the lower OXI4503 doses (Figure 2) or the CA4P dose used (Figure 1), it might suggest that the enhancement seen in combination with anti-CTLA-4 only occurs when a specific level damage is obtained. Here, CTLA4 is linked to neoplasm.